Kanser Dostu MEIS Proteinleri

Year 2022, , 156 - 160, 29.06.2022

Büşra Çimen , Abdullah Aslan

https://doi.org/10.46810/tdfd.995903

Abstract

Miyeloid kanser türünden ismini alan MEIS; enerji üretimini teşvik eden, ROS seviyelerini minimum düzeye indirmeye çalışan, kalp kası gelişim evresinde görev alan bir proteindir. Kanserli hücreler MEIS proteini metastaz için kullanmaktadır. MEIS proteini kanserli hücrelerde durdurmak amacıyla ‘kanseri kendi silahıyla vurma’ olarak tanımlanan MEIS protein inhibitörleri (MEISi) Türk akademisyen Fatih KOCABAŞ tarafından keşfedilmiş ve bu çalışma Uluslararası Hemotoloji-Onkoloji ödülüne layık görülmüştür. Yapılan çalışmada MEIS protein inhibitörleri meme ve pankreas gibi kanser türlerinden, %75 ve %95 gibi ciddi oranda kanserli hücrelerin yayılımını engellediği belirtilmiştir. Bu derlemede MEIS proteinlerinin; kanser türleri ve hastalıklar üzerindeki etkisi, MEIS inhibitörlerinin (MEISi) keşfiyle ilgili bilgilerden bahsedilmektedir.

Keywords

İnhibitör, Kanser, MeIs proteini, Metastaz

Cancer Friendly MEIS Proteins

Abstract

MEIS, named after the type of myeloid cancer; It is a protein that promotes energy production, tries to minimize ROS levels, and takes part in the development phase of the heart muscle. Cancerous cells use the MEIS protein for metastasis. In order to stop the MEIS protein in cancerous cells, MEIS protein inhibitors (MEISi), which are defined as 'shooting the cancer with its own weapon', have been discovered. It has been determined that MEIS protein inhibitors prevent the spread of cancerous cells, such as 75% and 95%, from cancer types such as chest and pancreas. In this review, MEIS proteins; Information about the effects on cancer types and diseases, the discovery of MEIS inhibitors (MEISi), the importance of MEIS protein inhibitors in cancer treatment are mentioned.

Keywords

Cancer, Inhibitor, MEIS proteins, Metastasis

References

• [1] Horozoğlu M. Uzman sistemler kullanılarak over (yumurtalık) kanseri tespiti. Selçuk Üniversitesi Fen Bilimleri Enstitüsü,Yüksek Lisans Tezi, Konya.; 2018.
• [2] Kocabaş F, et al. Identfication of cardiogenic and hematopoetic MEIS Inhibitors. Poster SessionI-Basic Science-Cardiac Biology and Physiology, Session held on 20 april P69.; 2018.
• [3] İnternet; 2019; Ekim 5. Erişim adresi: https://www.youtube.com/watch?v=zMp nW9N6R4
• [4] Sitwala KV, et al. HOX proteins and leukemia. Int J Clin Exp Pothol. 2008;1, 461-474.
• [5] Crist RC, et al. A conserved tissue-specific homeodomain-less isoform of MEIS1 is downregulated in colorectal cancer. Plos One. 2011;6, 1-7.
• [6] Morgado E, et al. Flt3 is dispensable to the HOXA9/MEIS1 leukemogenic cooperation. American Society of Hematology. 2007;109, 4020-4022. [7] Wong P, et al. MEIS 1 İs an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 2007;21, 2762-2774.
• [8] Wang Z, et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell. 2010;17, 597-608.
• [9] Aksöz M, et al. Emerging roles of Meis 1 cardias regeneration stem cells and canser. Current Drug Targets. 2018;19, 181-190.
• [10] İnternet; 2019; Ekim 5. Erişim adresi: https://www.ncbi.nlm.nih.gov/gene/4212
• [11] Svingen T, et al. Altered HOX gene expression in human skin and breast cancer cells. Cancer Biology Therapy. 2003; 2, 518-23.
• [12] Kelly ZL, et al. HOX genes in ovarian cancer, J Ovarian Res. 2011; 9, 4-16.
• [13] Owens BM, et al. Hox and non-hox homeobox genes in leukemic hematopoiesis. Stem Cell. 2002; 20, 364-79.
• [14] Verheije R, et al. Heterozygous loss-of-function variants of MEIS2 cause a triad of. European Journal of Human Genetics. 2018;27, 278-290.
• [15] Wang M, et al. MEIS2 regulates endothelial to hematopoietic transition of human embryonic stem cells by targeting TAL1. Stem Cell Research & Therapy. 2018;9, 1-13. [16] Calvo KR, et al. MEIS 1a suppresses differentiation by G-CSF and promotes proliferation by SCF: potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia. Proc Natl Acad Sci U S A. 2001;23,13120-13125.
• [17] Kroon E, et al. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2001;21, 224-234.
• [18] Wermuth PJ, et al. MEIS 1-mediated apoptosis is caspase dependent and can be suppressed by coexpression of HOXA9 in murine and human cell lines. Blood. 2005;105, 1222-1230.
• [19] Lin L, et al. Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in ewing sarcoma in co-operation with EWS-FLI1. Nucleic Acids Research. 2018.; 1-13, Doi: http://creativecommons.org/licenses/by/4.0,
• [20] Johng D, et al. HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer. Wıley The Prostate. wileyonlinelibrary.com/journal/pros. 2018.; 1-11.
• [21] Patel Av, et al. An shrna screen ıdentifies MEIS1 as a driver of malignant peripheral nerve sheath tumors. Ebiomedicine. 2016;9, 110- 119.
• [22] Yokoyama T, et al. MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis. The Journal of Clinical Investigation. 2016;126, 1664-1678.
• [23] Catoire H, et al. A direct interaction between two restless legs syndrome predisposing genes: MEIS1 And SKOR1. Scientific Reports. 2018; 8, 1-9.
• [24] Vegi NM, et al. MEIS2 ıs an oncogenic partner in aml1-eto-positive aml. Cell Reports. 2016;16, 498-507.
• [25] Xie R, et al. Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM. Cancer Cell. 2019;449, 31-44.
• [26] Giliberti A, et al. MEIS2 gene is responsible for intellectual disability cardiac defects and a distinct facial phenotype. 2019.; Doi: https://doi.org/10.1016/j.ejmg.2019.01.017. [27] Srivastava S, et al. Monogenic disorders that mimic the phenotype of rett syndrome. Neurogenetics. 2018;19, 41-47. [28] Yaguchi J, et al. Meis transcription factor maintains the neurogenic ectoderm and regulates the anterior-posterior patterning in embryos of a sea urchin Hemicentrotus Pulcherrimus. Developmental Biology. 2018;444 , 1–8.
• [29] Kocabaş F, et al. Hematopoietic and cardiogenic MEIS ınhibitors that enhance cellular proliferation and HDR gene expression. 5th International Congress of the Molecular Biology Association of Turkey (MolBiyoKon’17). 2017.; 8-10 September, Istanbul.
• [30] İnternet; 2019; Ekim 5. Erişim adresi: http://www.techin2b.com/techpremium.php?profile_id=v6AbMqrhHJf1&&log=0B0cSUvPeq&&from=1&&event=1
• [31] İnternet; 2019; Aralık 5. Erişim adresi: https://ru.linkedin.com/company/meinoxtech